For the patients, we must do better.
Where rare disease and CGT leaders make progress
Invite only. Closed door boardrooms, roundtables and selective partner showcases.
10th & 11th September 2025
Hyatt Regency Barcelona Tower, Spain
The 8th Annual CGTI Leaders Summit 2025
An invite only forum for up to 200 senior leaders in cell and gene therapy.
A captive programme with keynotes and fireside chats.
Curated one to one meetings and concierge introductions.
Selective partner showcases on CMC quality supply bioprocess and digital.
Runs alongside DDIF 2025 so discovery clinical and CMC align end to end and move faster to patients.
Decide faster. Scale smarter. Reach patients sooner.
WHO ATTENDS
-
C-suite and SVP/VP leaders in R&D, technical operations, manufacturing, quality and regulatory plus senior platform and product owners at therapy developers, CDMOs and enabling tech.
WHY ATTEND
-
Senior peer group with real mandates
-
Sessions that end with actions and owners
-
CMC, quality, regulatory, supply and digital
-
Select partner showcases for targeted demos
What makes it different
-
CGTI + DDIF connect discovery, clinical and CMC. Fewer handovers. Faster decisions. Better patient access.
-
Chatham House Rule.
-
Concierge intros on site
-
Selective booth near the boardrooms
-
Boardrooms and fireside talks
-
Leave with a 90-day plan and named owners
PAST SPEAKERS
Paolo Martini
Chief Research & Development Officer at ReAlta Life Sciences former CSO at Moderna
Warner Biddle
CEO at Kyverna Therapeutics former interim CEO at Kite a Gilead Company
Gwendolyn Binder PhD
President, Science and Technology at Cabaletta Bio
LEADERS SHAPING THE FUTURE
ADVISORY
“For the patients, we must do better."
ADVISORY
“Our very survival depends on our ability to stay awake, to adjust to new ideas, to remain vigilant and to face the challenge of change.” – Martin Luther King ...
These conversations matter - because the world can’t wait and neither can patients.
Invite only. Closed door boardrooms, roundtables and selective partner showcases.
SUMMIT INSIGHTS
200+
Up to 200 decision-makers in person. Previous attendee demographics include 50% EMEA, 30% America and 20% ROW
20%
20% best-of-breed vendors providing solutions to combat the manufacturing, scale-up & R&D hurdles of today's C>
06
Journey of CXO presentations. Six insightful, powerful and inspirational talks from CXOs in the industry
02
Exclusive in-person networking, over 2 days in Barcelona, on the 10th and 11th of September
7+
Pre-scheduled and pre-qualified one-to-one meetings with delegates who influence or make a decision
90%
Over 90% of our attendance provided positive feedback. Please click here to see what our delegation has to say
WHY ATTEND
Exploring opportunities for small-scale CDMOs
Insights into key pain points such as shortage of talent and rising costs of supply chain
A deep dive into emerging biopharma pipelines and innovative emerging technologies
New innovations and strategies driving costs down and improving the manufacturing process
The promises and challenges of new therapeutic modalities
Leveraging innovation to bridge the gap from Gene to GMP
Executive training for commercial innovation and how to make a profitable growth
Navigating pricing, market access and reimbursement framework
Regulatory updates and compliance
As the industry scales to meet global demand, leaders face mounting geopolitical pressures, supply chain volatility and regulatory complexity - all while driving scientific innovation and ensuring patient access.
This summit offers exclusive access to insights, strategies and connections that can’t be found anywhere else. It’s not just another conference - it’s where executives shape the future of cell and gene therapy.
ACTION
-
Scale CGT from portfolio to patient access
-
MSAT playbook for scale and comparability
-
Connected supply and site readiness
-
Digital and data for QA and RTRT
-
Evidence and access that work
-
AI from design to factory (CGTI × DDIF)
-
Data that travels (CGTI × DDIF)
OUTCOME
-
MSAT access and supply aligned for speed
-
Faster tech transfer right first time release
-
Chain of identity protected faster turnaround
-
Real time oversight right first time release
-
Improved literacy donor services measurable outcomes
-
Models to RTRT right first time batches
-
FAIR standards and lineage traceable decisions
IMPACT
-
Cycle time reduced
-
Faster tech transfer
-
Fewer chain errors
-
Fewer deviations faster release
-
Higher participation better outcomes
-
Shorter cycle time
-
Faster tech transfer
Agenda Insight
A private programme for senior leaders
Ends with action, outcome and impact in 90 days
FEATURED SPEAKERS 2025
For the patients, we must do better.
Together, we will.
Where rare disease and CGT leaders make progress
SPEAKERS 2025
PREVIOUS SPEAKERS SNAPSHOT
Be in the room where leaders decide
In CGT speed to clinical proof and scalable delivery set the pace. CGTI runs alongside DDIF 2025 so discovery clinical and CMC align end to end. Invite only. Chatham House Rule. Capped at 200 leaders. Closed door boardrooms, roundtables and selective partner showcases. Decisions not footfall. Outcomes in 90 days.
